Becton, Dickinson and Company $BDX Holdings Lifted by Skba Capital Management LLC

Skba Capital Management LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 1,619.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 57,514 shares of the medical instruments supplier’s stock after buying an additional 54,170 shares during the period. Skba Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $10,765,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of BDX. Dimensional Fund Advisors LP boosted its stake in shares of Becton, Dickinson and Company by 10.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,341,970 shares of the medical instruments supplier’s stock worth $438,267,000 after acquiring an additional 217,716 shares in the last quarter. Insigneo Advisory Services LLC boosted its position in shares of Becton, Dickinson and Company by 17.1% in the third quarter. Insigneo Advisory Services LLC now owns 2,907 shares of the medical instruments supplier’s stock worth $544,000 after buying an additional 425 shares during the period. Nautilus Advisors LLC acquired a new position in Becton, Dickinson and Company during the third quarter valued at $233,000. First Eagle Investment Management LLC lifted its stake in Becton, Dickinson and Company by 13.8% in the 3rd quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier’s stock worth $1,870,653,000 after acquiring an additional 1,208,218 shares in the last quarter. Finally, Strive Asset Management LLC purchased a new position in Becton, Dickinson and Company during the 3rd quarter valued at about $3,743,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of BDX stock opened at $174.17 on Wednesday. The firm’s 50 day moving average is $194.85 and its 200-day moving average is $191.75. The firm has a market capitalization of $49.59 billion, a price-to-earnings ratio of 28.41, a PEG ratio of 12.80 and a beta of 0.24. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The company had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company’s revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase program on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

Several brokerages recently issued reports on BDX. Citigroup cut their price objective on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Piper Sandler reaffirmed a “neutral” rating and set a $170.00 price objective (down from $205.00) on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Wells Fargo & Company dropped their target price on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 10th. Barclays started coverage on Becton, Dickinson and Company in a report on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 target price on the stock. Finally, Bank of America boosted their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research note on Monday, January 5th. Five equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $195.46.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director owned 36,763 shares of the company’s stock, valued at $6,713,291.43. This trade represents a 2.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 3,416 shares of company stock worth $674,693. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.